Stock Analysis

C.H. Robinson Worldwide Full Year 2023 Earnings: EPS Misses Expectations

Source: Shutterstock

C.H. Robinson Worldwide (NASDAQ:CHRW) Full Year 2023 Results

Key Financial Results

  • Revenue: US$17.6b (down 29% from FY 2022).
  • Net income: US$325.1m (down 65% from FY 2022).
  • Profit margin: 1.8% (down from 3.8% in FY 2022). The decrease in margin was driven by lower revenue.
  • EPS: US$2.74 (down from US$7.48 in FY 2022).
NasdaqGS:CHRW Earnings and Revenue Growth February 18th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

C.H. Robinson Worldwide EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Logistics industry in the US.

Performance of the American Logistics industry.

The company's shares are down 3.2% from a week ago.

Risk Analysis

You still need to take note of risks, for example - C.H. Robinson Worldwide has 2 warning signs we think you should be aware of.

Valuation is complex, but we're helping make it simple.

Find out whether C.H. Robinson Worldwide is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.